Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis.

Where this comes from

• Record sourced from PubMed, PMID 42447108.
• Also identified by DOI 10.1371/journal.pone.0353864 and PMC identifier 13367664.
• No licence information is recorded for this record.
• Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.